Diabetic Nephropathy Amelioration by a Low-Dose Sitagliptin in an Animal Model of Type 2 Diabetes (Zucker Diabetic Fatty Rat)
Open Access
- 30 November 2011
- journal article
- Published by Hindawi Limited in Experimental Diabetes Research
- Vol. 2011, 1-12
- https://doi.org/10.1155/2011/162092
Abstract
This study was performed to assess the effect of chronic low-dose sitagliptin, a dipeptidyl peptidase 4 inhibitor, on metabolic profile and on renal lesions aggravation in a rat model of type-2 diabetic nephropathy, the Zucker diabetic fatty (ZDF) rat. Diabetic and obese ZDF (fa/fa) rats and their controls ZDF (+/+) were treated for 6 weeks with vehicle (control) or sitagliptin (10 mg/kg/bw). Blood/serum glucose, HbA1c, insulin, Total-c, TGs, urea, and creatinine were assessed, as well as kidney glomerular and tubulointerstitial lesions (interstitial fibrosis/tubular atrophy), using a semiquantitative rating from 0 (absent/normal) to 3 (severe and extensive damage). Vascular lesions were scored from 0–2. Sitagliptin in the diabetic rats promoted an amelioration of glycemia, HbA1c, Total-c, and TGs, accompanied by a partial prevention of insulinopenia. Furthermore, together with urea increment prevention, renal lesions were ameliorated in the diabetic rats, including glomerular, tubulointerstitial, and vascular lesions, accompanied by reduced lipid peroxidation. In conclusion, chronic low-dose sitagliptin treatment was able to ameliorate diabetic nephropathy, which might represent a key step forward in the management of T2DM and this serious complication.Keywords
Funding Information
- Merck
This publication has 60 references indexed in Scilit:
- Incretins: Clinical Perspectives, Relevance, and Applications for the Primary Care Physician in the Treatment of Patients With Type 2 Diabetes MellitusMayo Clinic Proceedings, 2010
- Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat)Mediators of Inflammation, 2010
- SitagliptinDrugs, 2010
- Role of the renin angiotensin system in diabetic nephropathyWorld Journal of Diabetes, 2010
- Les facteurs de progression de la néphropathie diabétique : prise en charge et évolutionNephrologie & Therapeutique, 2009
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes MellitusDiabetes, 2009
- The incretins: From the concept to their use in the treatment of type 2 diabetes. Part A: Incretins: Concept and physiological functionsDiabetes & Metabolism, 2008
- Relation of Low Glomerular Filtration Rate to Metabolic Disorders in Individuals without Diabetes and with NormoalbuminuriaClinical Journal of the American Society of Nephrology, 2008
- Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetesDiabetes & Metabolism, 2008
- Podocyte injury underlies the progression of focal segmental glomerulosclerosis in the fa/fa Zucker ratKidney International, 2001